Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$32.31 - $52.32 $743,130 - $1.2 Million
23,000 New
23,000 $47.3 Million
Q4 2018

Feb 12, 2019

SELL
$8.73 - $13.74 $873 - $1,374
-100 Reduced 0.02%
550,000 $0
Q3 2018

Nov 09, 2018

BUY
$12.7 - $15.79 $4.42 Million - $5.49 Million
347,800 Added 171.92%
550,100 $303,000
Q1 2018

May 11, 2018

BUY
$27.95 - $45.04 $5.65 Million - $9.11 Million
202,300 New
202,300 $838,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $745M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.